# Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

> **NCT00988494** · PHASE2 · COMPLETED · sponsor: **Santen Pharmaceutical Co., Ltd.** · enrollment: 45 (estimated)

## Conditions studied

- Persistent Corneal Epithelial Defect

## Interventions

- **DRUG:** DE-105 ophthalmic solution
- **DRUG:** DE-105 ophthalmic solution
- **DRUG:** Placebo ophthalmic solution

## Key facts

- **NCT ID:** NCT00988494
- **Lead sponsor:** Santen Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2012-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988494, "Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00988494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*